Kettner Griswold (19, Bethesda, MD) and Paul Sebexen (19, Staten Island, NY) are stopping out of school to work on a benchtop genome synthesis device, which will allow individual laboratories and medical practices to synthesize large genetic constructs in-house for an unprecedented low recurring cost. This product would massively disrupt the fields of biotechnology and health care, fueling innovation and stimulating interest and research sector-wide.